Molecular characterization of *ERBB2*-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases

Daniel R. Owen,[1,2] Hui-li Wong,[3] Melika Bonakdar,[4] Martin Jones,[4] Christopher S. Hughes,[4] Gregg B. Morin,[4,5] Steven J.M. Jones,[4,5] Daniel J. Renouf,[3] Howard Lim,[3] Janessa Laskin,[4,5] Marco Marra,[4,5] Stephen Yip,[1,2] and David F. Schaeffer[1,2]

[1]Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada; [2]Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia V5Z 1M9, Canada; [3]Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E63, Canada; [4]Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4S6, Canada; [5]Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6H 3N1, Canada

Corresponding author:
daniel.owen@alumni.ubc.ca

Ontology terms: neoplasm of the gastrointestinal tract; neoplasm of the large intestine

Abstract *ERBB2* amplification has been identified in ∼5% of *KRAS* wild-type colorectal cancers (CRCs). A recent clinical trial showed response to HER2-directed therapy in a subset of *ERBB2*-amplified metastatic CRCs resistant to chemotherapy and EGFR-directed therapy. With the aim of better understanding mechanisms of resistance to HER2-directed and EGFR-directed therapies, we report the complete molecular characterization of two cases of *ERBB2*-amplified CRC. PCR-free whole-genome sequencing was used to identify mutations, copy-number alterations, structural variations, and losses of heterozygosity. *ERBB2* copy number was also measured by fluorescence in situ hybridization. Single-stranded mRNA sequencing was used for gene expression profiling. Immunohistochemistry and protein mass spectrometry were used to quantify HER2 protein expression. The cases showed *ERBB2* copy number of 86 and 92, respectively. Both cases were immunohistochemically positive for HER2 according to CRC-specific scoring criteria. Fluorescence in situ hybridization and protein mass spectrometry corroborated significantly elevated *ERBB2* copy number and abundance of HER2 protein. Both cases were microsatellite stable and without mutation of RAS pathway genes. Additional findings included altered expression of *PTEN*, *MET*, and *MUC1* and mutation of *PIK3CA*. The potential effects of the molecular alterations on sensitivity to EGFR and HER2-directed therapies were discussed. Identification of *ERBB2* amplification in CRC is necessary to select patients who may respond to HER2-directed therapy. An improved understanding of the molecular characteristics of *ERBB2*-amplified CRCs and their potential mechanisms of resistance will be useful for future research into targeted therapies and may eventually inform therapeutic decision-making.

[Supplemental material is available for this article.]

INTRODUCTION

Amplification of *ERBB2* has been detected in ~2%–4% of unselected colorectal cancer (CRC) cases and a strong concordance with overexpression of HER2 protein has been demonstrated using immunohistochemistry (IHC) (Ooi et al. 2004; Marx et al. 2010; The Cancer Genome Atlas Network 2012). CRC-specific criteria for assessing HER2 positivity by IHC and fluorescence in situ hybridization (FISH) have been developed (Valtorta et al. 2015). *ERBB2* amplification is one of several proposed mechanisms of resistance to epidermal growth factor receptor (EGFR) blockade in *KRAS* wild-type CRC (Bertotti et al. 2015). The HERACLES trial identified HER2 positivity in 5% of *KRAS* wild-type metastatic CRC showing resistance to standard therapy, including EGFR-directed therapy (Sartore-Bianchi et al. 2016). Among patients treated with combination trastuzumab and lapatinib, 30% had a partial or complete response and 30% had disease stabilization lasting 16 or more weeks.

Post hoc analysis of the HERACLES trial data indicated that an *ERBB2* copy number of >9.45 best identified patients who responded to HER2-directed therapy. However, a subset of patients responded poorly or did not respond to HER2-directed therapy despite high *ERBB2* copy number, indicating that additional molecular alterations are likely associated with resistance to HER2-directed therapy.

Alteration of RAS pathway genes is a potential mechanism of resistance to HER2-directed therapy, although the majority of *ERBB2*-amplified CRCs studied to date appear to have been wild type in RAS pathway genes (Bertotti et al. 2011; Valtorta et al. 2015; Sartore-Bianchi et al. 2016). Patients included in the HERACLES trial were required to have wild-type status of *KRAS* codons 12 and 13. However, neither *KRAS* mutations outside of codons 12 and 13 nor mutations in other RAS pathway genes were excluded in patients enrolled in the HERACLES trial. Additional mutational testing following the HERACLES trial revealed a *BRAF* V600E mutation in one patient whose tumor progressed during the trial and a *KRAS* A146T mutation in another whose disease was stable. RAS pathway alterations that are not detected in routine molecular testing of CRC have the potential to confer resistance to HER2-directed therapy. Pretreatment of *ERBB2*-amplified CRC with EGFR-directed therapy may also select for clonal populations of tumor cells harboring RAS pathway alterations that have the potential to confer resistance to HER2-directed therapy. All patients in the HERACLES trial were pretreated with EGFR-directed therapy.

The ongoing Personalized Oncogenomics Group (POG) trial (NCT02155621) has undertaken complete molecular characterization of a total of 60 patients with metastatic CRC, including 29 *KRAS* wild-type tumors, two of which showed high-level amplification of *ERBB2*. An improved understanding of the molecular characteristics of *ERBB2*-amplified CRCs and their potential mechanisms of resistance to HER2-directed therapy may influence the direction of future research on targeted therapies and inform future therapeutic decision-making. With these aims, we report the whole genome and transcriptome molecular profiling of the two *ERBB2*-amplified CRCs in the POG trial.

RESULTS (CASE 1)

Clinical Presentation

A 45-yr-old man presented with hematochezia and rectal pain. Imaging demonstrated extensive liver and lung lesions, along with soft tissue thickening of the rectum. He had a history of asthma but was otherwise well. His family history was unremarkable apart from an uncle who was diagnosed with CRC.

Colonoscopic biopsy confirmed the diagnosis of primary rectal adenocarcinoma and he received a palliative rectal resection. Histology showed a well-differentiated

Figure 1. Morphologic, immunohistochemical, and fluorescence in situ hybridization (FISH) findings in Case 1. (*A*) Well-differentiated rectal adenocarcinoma, hematoxylin and eosin staining at 100× magnification. (*B*) HER2 3$^+$ positivity, immunohistochemical staining at 100× magnification. (*C*) FISH with HER2 probe and chromosome enumeration probe 17 (CEP 17) showing high-level HER2 amplification.

adenocarcinoma (Fig. 1A) located at the upper rectum with lymphovascular invasion, extension into the mesorectum, extramural tumor deposits, and involvement of 1 out of 28 perirectal lymph nodes. IHC testing of the tumor showed normal mismatch repair (MMR) protein expression. Tumor gene sequencing revealed no mutations in exons 12 or 13 of the *KRAS* gene.

The patient was commenced on first-line therapy with 5-fluorouracil, irinotecan, and bevacizumab and had an excellent radiologic and biochemical response sustained for just >2 yr before disease progression. Tumor within his liver was then sampled by ultrasound-guided core needle biopsy and submitted to the POG trial for complete molecular characterization.

Genomic Analyses

Whole-genome analysis demonstrated 162 nonsynonymous mutations in protein coding genes, including 157 single-nucleotide variations (SNVs) and five insertion or deletion mutations (indels) representing the 83rd and 68th percentile for mutation burden compared to The Cancer Genome Atlas (TCGA) CRC data set. In keeping with tumor retention of IHC staining for MMR proteins, genomic analysis showed no evidence of MMR deficiency. No increased expression of *CD274*, the PD-L1 checkpoint inhibitor coding gene, was detected. No specific characteristic mutational signature was identified. Numerous large regional copy-number alterations and losses of heterozygosity were detected throughout the genome. The point mutations, small insertion/deletion mutations, gene copy-number alterations, and expression level alterations that are relevant to the discussion of potential mechanisms of resistance to HER2-directed therapy in Case 1 are summarized in Table 1.

Receptor Tyrosine Kinase Pathways

HER2 IHC staining performed on the primary rectal resection showed intense (3+), circumferential staining of all tumor cells, interpreted as HER2$^+$ according to CRC-specific scoring criteria (Fig. 1B; Valtorta et al. 2015). All other molecular testing, including FISH and protein mass spectrometry, was performed on tumor sampled from the patient's liver after first-line chemotherapy and bevacizumab. *ERBB2* had 92 copy gains and approximately 33-fold increased gene expression, corresponding to 98th percentile expression compared to TCGA CRC data set (Fig. 2). FISH also showed a very high *ERBB2* copy number (Fig. 1C).

Table 1. Point mutations, small insertion/deletion mutations (indels), gene copy-number alterations, and expression level alterations relevant to potential mechanisms of resistance to HER2-directed therapy in Case 1

Gene	Chromosome	DNA reference	Protein reference	dbSNP ID	Variant type	Genotype	Predicted effect
PIK3CA	3q26.3	NM_006218.3:c.112C>T	p.Arg38Cys	749415085	SNV_substitution	Heterozygous	Likely pathogenic; strong gain of function
APC	5q22.2	NM_000038.5:c.847C>T	p.Arg283Ter	786201856	SNV_nonsense mutation	Heterozygous	Pathogenic; loss of function
APC	5q22.2	NM_000038.5(APC): c.3927_3931delAAAGA	p.Ile1309fs	121913224	deletion_frameshift	Heterozygous	Pathogenic; loss of function
TP53	17p13.1	NM_000546.5:c.919 +1G>T	p.Xnspl	1131691039	SNV_splice donor	Homozygous	Likely pathogenic; loss of function

Gene	Chromosome	DNA reference	Copy change	CNV state	Expression (RPKM)	Expression fold change versus Normal colon	Expression percentile compared to TCGA COAD/ READ
ERBB2	17q12	NM_004448.3	+92	Amplification	230	+33	98
MET	7q31.2	NM_000245.3	+1	Gain	48	+6.7	93
PTEN	10q23.3	NM_000314.6	+1	Gain	5.1	−4.1	2

RPKM, reads per kilobase of transcript per million mapped reads; TCGA COAD/READ, the mRNA expression level reported by The Cancer Genome Atlas for colon adenocarcinoma and rectum adenocarcinoma.

Protein mass spectrometry showed a 5.3-fold increase in HER2 compared to normal colon. Increased mRNA expression of *ERBB3* was not detected.

The receptor tyrosine kinase gene *MET* showed a single copy gain and 6.7-fold increased gene expression, corresponding to 93rd percentile expression compared to TCGA CRC data set. No mutations in RAS/RAF pathway genes were identified. A gain-of-function mutation in *PIK3CA* was detected and *PTEN* showed 4.1-fold reduced gene expression, corresponding to 2nd percentile expression compared to TCGA CRC data set.


Figure 2. Increased mRNA expression of *ERBB2* in Case 1. Histogram showing *ERBB2* mRNA expression level in Case 1 (vertical red line) expressed as the common logarithm of reads per kilobase of transcript per million mapped reads ($\log_{10}$ RPKM) compared to cases from the TCGA CRC data set (counted as vertical orange bars).

Cell Cycle and Apoptosis Pathways

Biallelic deleterious mutations in *APC* and *TP53* are in keeping with tumor evolution through the chromosomal instability pathway of colorectal carcinogenesis. A homozygous loss-of-function mutation of *TP53* was identified. Alterations of the Wnt signaling pathway included heterozygous nonsense and frameshift mutations in *APC* as well as increased expression of downstream targets including *MYC*, *CCND1*, and *MMP7*. Homozygous deletions of cyclin-dependent kinase inhibitors, *CDKN2A* and *CDKN2B*, were detected.

Treatment Outcomes

The patient received second-line chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX). His metastatic disease progressed again after 5 months, and he was switched to a third-line regimen of irinotecan with cetuximab. Upon further progression, he was again switched to regorafenib. Based on the molecular characterization of his tumor there was a consideration of therapy with trastuzumab and lapatinib, but no clinical trial with these agents was available to him at the time of progression.

RESULTS (CASE 2)

Clinical Presentation

Imaging demonstrated bulky liver and pelvic masses and enlarged abdominal lymph nodes in a 49-yr-old woman who had presented with a short history of abdominal pain and distension. She had no concurrent medical problems and no significant family history of malignancy. Colonoscopic biopsy revealed a moderately differentiated colorectal adenocarcinoma in the transverse colon (Fig. 3A). IHC testing of the tumor revealed a normal MMR profile and no *BRAF* V600E mutation. Tumor gene sequencing revealed no mutations in exons 12 or 13 of the *KRAS* gene. Tumor tissue was obtained for molecular analysis by a second colonoscopic biopsy prior to the initiation of first-line chemotherapy with 5-fluorouracil, irinotecan (FOLFIRI), and bevacizumab.

Genomic Analyses

Whole-genome analysis revealed 70 nonsynonymous mutations in protein coding genes, including 64 SNVs and 6 indels, representing 23rd and 39th percentile for mutation burden

Figure 3. Morphologic and immunohistochemical Findings in Case 2. (*A*) Moderately differentiated adenocarcinoma of the transverse colon, hematoxylin and eosin staining at 100× magnification. (*B*) HER2 3[+] positivity, immunohistochemical staining at 100× magnification.

Table 2. Point mutations, small insertion/deletion mutations (indels), gene copy-number alterations and expression level alterations relevant to potential mechanisms of resistance to HER2-directed therapy in Case 2

Gene	Chromosome	DNA reference	Protein reference	dbSNP ID	Variant type	Genotype	Predicted effect
APC	5q22.2	NM_000038.5:c.1682delA	p.Lys561fs	NA[a]	SNV_frameshift mutation	Heterozygous	Likely pathogenic; loss of function (inferred)
APC	5q22.2	NM_000038.5:c.3956delC	p. p.Pro1319fs	1057517558	SNV_frameshift mutation	Heterozygous	Pathogenic; loss of function
TP53	17p13.1	NM_000546.5:c.743G>A	p.Arg248Gln	11540652	Deletion_substitution	Homozygous	Pathogenic; loss of function

Gene	Chromosome	DNA reference	Copy change	CNV state	Expression (RPKM)	Expression fold change versus Normal colon	Expression percentile compared to TCGA COAD/READ
ERBB2	17q12	NM_004448.3	+86	Amplification	810	+120	100
MET	7q31.2	NM_000245.3	+1	Gain	25	+3.6	52
PTEN	10q23.3	NM_000314.6	0	Neutral	6.1	−3.5	5
MUC1	1q22	NM_002456.5	+1	Gain	170	+26	88
MTOR	1p36.2	NM_004958.3	1	Gain	11	+2.1	91

RPKM, reads per kilobase of transcript per million mapped reads; TCGA COAD/READ, the mRNA expression level reported by The Cancer Genome Atlas for colon adenocarcinoma and rectum adenocarcinoma.
[a]This single-nucleotide deletion has not previously been reported. *APC* loss of function is inferred because this is a frameshift mutation. The finding has been submitted to dbSNP for assignment of a variant ID.

compared to TCGA CRC data set. A mutational signature correlating strongly with patient age at cancer diagnosis was detected (Alexandrov et al. 2013).

Low expression of MMR genes (*MLH1*, *PMS1*, *PMS2*, and *MGMT*) was identified. However, the tumor showed low mutation burden, no genomic evidence of microsatellite instability, and intact IHC expression of MMR proteins. Increased expression of *CD274* was not detected. Numerous large regional copy-number alterations and losses of heterozygosity were detected throughout the genome. The point mutations, small insertion/deletion mutations, gene copy-number alterations, and expression level alterations that are relevant to the discussion of potential mechanisms of resistance to HER2-directed therapy in Case 2 are summarized in Table 2.

Receptor Tyrosine Kinase Pathways

Several genes involved in the MAP kinase and PI3K–AKT–mTOR pathways had amplification and increased expression. *ERBB2* had 86 copy gains and approximately 120-fold increased gene expression, corresponding to 99th percentile expression compared to TCGA CRC data set (Fig. 4). IHC staining with HER2 antibody also showed intense (3[+]), circumferential staining of all tumor cells, interpreted as HER2[+] according to CRC-specific scoring criteria (Fig. 3B).

The receptor tyrosine kinase *MET* had 3.6-fold increased gene expression, corresponding to 52nd percentile expression compared to TCGA CRC data set. *PTEN*, a negative regulator of the PI3K–AKT–mTOR pathway, had 3.5-fold decreased gene expression, corresponding to 5th percentile expression compared to TCGA CRC data set. *MUC1*, a

Figure 4. Increased mRNA expression of *ERBB2* in Case 2. Histogram showing *ERBB2* mRNA expression level in Case 2 (vertical red line) expressed as the common logarithm of reads per kilobase of transcript per million mapped reads ($\log_{10}$ RPKM) compared to cases from the TCGA CRC data set (counted as vertical orange bars).

gene that encodes a cell surface mucin protein shown to activate several pathways, including the PI3K–AKT–mTOR, MAP kinase, and Wnt signaling pathways (Kufe 2013), had ~26-fold increased gene expression, corresponding to 88th percentile expression compared to TCGA CRC data set. *MTOR* had 2.1-fold increased gene expression, corresponding to 91st percentile expression compared to TCGA CRC data set. The level of *ERBB3* expression was very low.

NRAS, *BRAF*, and *MAP3K9* all had increased expression, and *NF1*, a negative regulator of the MAP kinase pathway, had decreased expression. Downstream transcription factors, *MYCN*, *ETV4*, *SKP2*, and *ELK4* all had markedly increased expression. Increased expression of *BRD4* and *NOTCH1* were inferred drivers of *MYCN* and *SKP2* expression, respectively.

Cell Cycle Pathways

Deregulation of the cell cycle was evident from altered expression of several genes. Increased expression of *EZH2* and repression of the cell cycle regulator, *CDKN2A*, were detected. *CDKN1B* showed a low level of expression and degradation of its protein product, p27^{Kip1}, is an expected consequence of increased *SKP2* expression. Copy gains of *CDK6* and *CCNE2*, as well as increased expression of both genes, were detected. *PLK1* and *AURKA*, facilitators of cell cycle progression, also had copy gains and markedly increased expression.

WNT Pathway and TP53

Biallelic deleterious mutations in *APC* and *TP53* are in keeping with tumor evolution through the chromosomal instability pathway of colorectal carcinogenesis. *APC* showed biallelic loss-of-function frameshift mutations. *CTNNB1* targets, including *GAST* and *BIRC5*, had an overall pattern of up-regulation. *TP53* harbored a homozygous mutation known to result in mutant p53 protein with both loss of tumor suppressor properties and gain of oncogenic properties (Freed-Pastor and Prives 2012).

Treatment Outcomes

The patient had an excellent clinical, radiological, and biochemical response to her initial chemotherapy. The patient had 38 cycles of leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI) with bevacizumab until radiological progression was noted. She has subsequently

initiated therapy with FOLFOX. Upon progression, she may be eligible for a clinical trial of HER2-directed therapy, through the CCTG CAPTUR clinical trial (NCT03297606).

DISCUSSION

The genomic landscape of *ERBB2*-amplified CRC is not yet described in detail. All tumors in the HERACLES trial tested HER2[+] and progressed despite EGFR-directed therapy. A subset of the tumors also did not respond to HER2-directed therapy (Sartore-Bianchi et al. 2016). Most *ERBB2*-amplified CRCs studied to date have been wild-type in RAS and RAF pathway genes. The reasons that some *ERBB2*-amplified CRCs do not respond to EGFR, and HER2-directed therapy has not been fully explored. We report the complete molecular characterization of two *ERBB2*-amplified CRCs identified in the ongoing POG trial with the primary aim of generating hypotheses about the potential mechanisms of resistance to EGFR-directed and HER2-directed therapy. Although neither patient with *ERBB2*-amplified CRC identified in the POG trial has yet received HER2-directed therapy, the patients may seek government funding or enrollment in a clinical trial to receive trastuzumab and lapatinib.

ERBB2 amplification has been reported to correlate with a lack of response to EGFR-directed therapy (Martin et al. 2013; Jeong et al. 2017) and is a potential explanation for the patient's lack of response to cetuximab in Case 1. Several other molecular alterations have been associated with resistance to EGFR-directed therapy in CRC (Bertotti et al. 2015), although none were detected in Case 1. Although we detected decreased expression of *PTEN* and an activating mutation in exon 2 of *PIK3CA*, neither alteration is expected to affect prognosis or to predict response to cetuximab (Karapetis et al. 2014; Llovet et al. 2015) and the College of American Pathologists cites a lack of sufficient evidence to recommend analysis of *PIK3CA* and *PTEN* for selection of therapy in CRC, except in the setting of clinical trials (Sepulveda et al. 2017). The patient described in Case 2 has not yet received EGFR-directed therapy but she does not harbor any resistance-associated molecular alterations, other than *ERBB2* amplification.

Patients required wild-type status of *KRAS* codons 12 and 13 for inclusion in the HERACLES trial, but, following the trial, plasma-based mutational analysis revealed a *BRAF* V600E mutation in one patient and a *KRAS* A146T mutation in another. *KRAS* A146T mutation has been shown not to affect sensitivity to EGFR-directed therapy in CRC (De Roock et al. 2010). Data on whether or not *BRAF* V600E mutation predicts a lack of response to EGFR-directed therapy in CRC are inconclusive, and the use of *BRAF* V600E as a predictive marker in CRC is not currently recommended (Sepulveda et al. 2017). Additional molecular alterations that were not identified over the course of the HERACLES trial may have contributed to the observed resistance to EGFR and HER2-directed therapies.

Strong concordance between *ERBB2* amplification and IHC overexpression of HER2 protein has been demonstrated in CRC (Ooi et al. 2004). Both cases in our cohort are *ERBB2*-amplified, *KRAS* wild-type CRCs correctly identified as HER2[+] by IHC using newly proposed CRC-specific scoring criteria (Valtorta et al. 2015). In Case 1, FISH analysis and protein mass spectrometry also showed numerous *ERBB2* copy gains and increased HER2 protein expression.

Quantification of *ERBB2* copy number and HER2 protein expression by analyses such as quantitative IHC (Jensen et al. 2017), PCR, FISH, and protein mass spectrometry has a potential advantage over nonquantitative or semiquantitative detection of HER2 positivity. Data from the HERACLES trial suggested that higher levels of *ERBB2* amplification are associated with an increased likelihood of response to HER2-directed therapy in CRC (Sartore-Bianchi et al. 2016). Quantification of HER2 protein expression in breast and gastric cancer has also suggested that higher levels of HER2 protein may predict increased likelihood of

response to HER2-directed therapy (Bang et al. 2010; Scaltriti et al. 2015). The use of mass spectrometry to quantify the level of HER2 protein expression in CRC is feasible. However, further study will be required to determine whether this relatively novel method of HER2 protein quantification can reliably be used to predict response to HER2-directed therapy.

The very high-level of *ERBB2* amplification is a potential driver of tumorigenesis in both cases in our cohort, although *ERBB2* amplification and HER2 protein overexpression do not always indicate that HER2-directed therapy will be effective. A subset of patients in the HERACLES trial designated as HER2[+] and shown to have high *ERBB2* copy numbers suffered disease progression while on HER2-directed therapy (Sartore-Bianchi et al. 2016). Numerous potential mechanisms of resistance to HER2-directed therapy have been identified, mostly through studies involving breast and gastric cancer (Montemurro and Scaltriti 2014).

Although the effect of PI3K pathway activation on the sensitivity of CRC to HER2-directed therapy has not been directly investigated, activating mutations of *PIK3CA* and decreased expression of *PTEN* have been identified as potential mechanisms of resistance to trastuzumab and lapatinib in breast cancer (Berns et al. 2007; Wang et al. 2011). A study using breast cancer cell lines and mouse xenografts demonstrated that activating mutations of *PIK3CA* and decreased expression of *PTEN* confer resistance to lapatinib that is reversible by a drug that inhibits both PI3K and mTOR (Eichhorn et al. 2008). However, data from randomized controlled trials have been conflicting (Dave et al. 2011; Loi et al. 2013; Perez et al. 2013), and the evidence is insufficient to confirm that PI3K pathway alterations, as observed in Case 1, would confer resistance to HER2-directed therapy. T-DM1, a conjugation of trastuzumab with emtansine, a chemotherapeutic agent, appears to overcome trastuzumab resistance in breast cancer by bypassing *PIK3CA* activating mutations downstream from the HER2 receptor (Baselga et al. 2016). A trial of T-DM1 in patients with HER2[+] CRC who have shown disease progression in the HERACLES trial is currently ongoing (Siena et al. 2016). Although no *PIK3CA* activating mutation was identified in Case 2, decreased expression of *PTEN* and increased expression of *MTOR*, as were identified in Case 2, could limit the effectiveness of HER2-directed therapy even if combined with drugs that act downstream from *PIK3CA*.

Although mutations of *KRAS*, *NRAS*, and *BRAF* are not often associated with *ERBB2* amplification in CRC (Bertotti et al. 2011; The Cancer Genome Atlas Network 2012; Valtorta et al. 2015), they could account for some cases of resistance to HER2-directed therapy. Discordance of *KRAS* status between primary and metastatic CRC has been reported as low as 2% (Vakiani et al. 2012) but may be as high as 20% (Lee et al. 2015), suggesting that some cases of CRC may have heterogeneity in the mutational status of RAS pathway genes. Furthermore, the effect of chemotherapy and EGFR-directed therapy on the mutational status of RAS pathway genes in CRC is not well studied. Chemotherapy and EGFR-directed therapy may select for tumor cell populations harboring RAS pathway mutations, even in tumors which are identified as wild-type on pretreatment mutational testing. Therefore, reevaluation of the mutational status of RAS pathway genes prior to the initiation of HER2-directed therapy may be warranted in patients who have received chemotherapy and EGFR-directed therapy.

Clinical testing of both primary colorectal tumors in Cases 1 and 2 occurred prior to the initiation of chemotherapy and targeted therapy; both tumors were wild-type for *BRAF* and *KRAS* codons 12 and 13. The primary colorectal tumor in Case 1 was identified as HER2[+] by IHC prior to the initiation of chemotherapy and targeted therapy. The molecular features of Case 1 were extensively reanalyzed 2 years later, as part of the POG trial, using tissue obtained from a metastatic liver lesion following progression on first-line therapy consisting of 5-fluorouracil, irinotecan, and bevacizumab. *ERBB2*-amplification and the mutational status of RAS pathway genes in Case 1 was concordant between the colorectal primary tumor and the liver metastasis.

Marx and colleagues have previously identified heterogeneity of *ERBB2* amplification, both within primary tumor and at metastatic sites, in four cases of CRC (Marx et al. 2010). However, none of the *ERBB2*-amplified CRC cases in the study by Marx and colleagues showed <40% of tumor cells positive for *ERBB2* amplification in either the primary tumor or at metastatic sites. Future studies correlating heterogeneity of *ERBB2* amplification with response to HER2-directed therapy in CRC are warranted. CRC with heterogeneity of *ERBB2* amplification has the potential for at least partial response to HER2-directed therapy if a significant proportion of tumor cells are *ERBB2*-amplified. However, heterogeneity of amplification remains a potential explanation for the lack of response to HER2-directed therapy observed in some cases of *ERBB2*-amplified CRC, such as those in the HERACLES trial.

Concordance in *ERBB2* amplification between tumor sampled before and after treatment in Case 1 suggests that chemotherapy and bevacizumab do not select against tumor cells harboring *ERBB2* amplification. Unfortunately, the data collected on Case 1 did not allow for the comparison of *ERBB2* amplification in samples collected before and after administration of cetuximab. Comparisons between primary and metastatic tumor and comparisons pre- and posttreatment could not be performed in Case 2 because only tissue biopsied from the patient's primary transverse colon tumor prior to treatment was made available for testing. Future research should include additional *ERBB2*-amplified CRCs with primary and metastatic tumor sampled before and after administration of relevant chemotherapeutic agents and targeted therapies.

Trastuzumab is effective against HER2$^+$ breast cancer because it interferes with the dimerization between HER2 and HER3, thereby decreasing the activity of downstream signaling pathways such as the PI3K–AKT–mTOR pathway (Junttila et al. 2009). Lapatinib, an inhibitor of the tyrosine kinase function of HER2, is also used to treat patients with HER2$^+$ metastatic breast cancer whose disease has progressed despite HER2-directed antibody therapy. However, up-regulation of *ERBB3*, a mechanism of resistance to lapatinib, leads to sustained activation of the PI3K–AKT–mTOR pathway and reduces the effectiveness of PI3K/AKT inhibitors (Chandarlapaty et al. 2011; Garrett et al. 2011; Montemurro and Scaltriti 2014). Both cases in our cohort showed low expression of *ERBB3*, although neither patient had yet received lapatinib or any other HER2-directed therapy at the time of data collection. Activation of the PI3K pathway may account for the lack of response to trastuzumab and lapatinib in some of the CRC cases in the HERACLES trial. However, the data on the effect of PI3K pathway alterations are presently insufficient to predict response to HER2-directed therapy in HER2$^+$ CRC.

Increased expression of *MET*, the gene encoding a receptor tyrosine kinase that activates both the PI3K and MAPK pathways, was identified in both cases. High levels of c-MET and HER2 have previously been demonstrated in CRC (Yao et al. 2013). Interaction between HER2 and MET is also a proposed mechanism of resistance to trastuzumab in breast cancer (Shattuck et al. 2008; Paulson et al. 2013). Multiple clinical trials investigating the MET receptor as a therapeutic target in CRC are ongoing and at least one has shown promising initial results (Rimassa et al. 2015). MET-directed therapy as a means of overcoming resistance to HER2-directed therapy warrants further study.

High-level expression of *MUC1*, the gene encoding a cell surface protein shown to activate the PI3K–AKT–mTOR and MAP kinase pathways and to participate in nuclear signaling alongside Wnt/β-catenin, STAT, and NF-κB (Li et al. 2003; Kufe 2013), was identified in Case 2. Immunohistochemical expression of MUC1 protein correlates with an increased risk of lymph node and distant metastasis in CRC (Zeng et al. 2015) and increased tumor stage in non-MMR deficient CRC (Lugli et al. 2007). High-level *MUC1* expression is also a potential mechanism of resistance to HER2-directed therapy. Although interaction between MUC1 and HER2 in CRC has not been extensively studied, a correlation between immunohistochemical expression of MUC1 and HER2 has been identified (Asonuma et al. 2013).

GO-203, a peptide inhibitor of MUC1-C, reduces trastuzumab resistance and inhibits survival of breast cancer cells (Raina et al. 2014) and has also been shown to reduce growth of CRC cell cultures and mouse xenografts (Ahmad et al. 2017). A preclinical study suggested that a vaccine strategy targeting MUC1 protein in CRC is feasible and may enhance production of anti-MUC1 antibodies (Zheng et al. 2014). Tumor vaccine strategies targeting MUC1 protein in breast, lung, colorectal, and other cancers have been in clinical trials for the past few years (Wurz et al. 2014); however, many of the trials have now been terminated because of mixed or negative results. If future treatment strategies targeting MUC1 protein are successful, further study of the interaction between MUC1 and HER2 in CRC and other tumors is warranted, as *MUC1* expression may affect sensitivity to HER2-directed therapy.

CONCLUSIONS

The POG trial has identified two *KRAS* wild-type CRCs showing high-level expression of *ERBB2* that also tested HER2$^+$ according to newly developed CRC-specific IHC criteria. No data on the effectiveness of HER2-directed therapy are available for either patient in our cohort. However, given the promising results of the HERACLES trial, a trial of HER2-directed therapy would be worthwhile in both patients, particularly once they have exhausted all other lines of proven therapy.

Techniques that quantify the level of HER2 protein expression may be superior to non-quantitative IHC detection of HER2 positivity because CRCs with high-level HER2 protein expression, such as those identified in the POG and HERACLES trials, are thought more likely to respond to HER2-directed therapy. Several molecular alterations that could confer resistance to HER2-directed therapy, such as increased expression of *MUC1* and *MET*, decreased expression of *PTEN*, and activating mutations in *PIK3CA*, have been identified in our cohort. Similar molecular alterations may account for the resistance to HER2-directed therapy observed in the HERACLES trial. Despite the potential for resistance, the results of the HERACLES trial indicate that HER2-directed therapy is beneficial for a substantial proportion of patients with HER2$^+$ CRC. Further study into the potential mechanisms of resistance is necessary for the selection of appropriate targeted therapies and for the development of novel treatment approaches in *ERBB2*-amplified CRC.

METHODS

Genomic and Transcriptomic Analysis
Patient Enrollment

Patients were enrolled in our ongoing study at the BC Cancer Agency in Vancouver, British Columbia, entitled POG, which enrolls patients with metastatic cancers of all subtypes. Individual's cancers undergo whole-genome DNA and RNA sequencing and in-depth bioinformatic analyses to identify somatic variants and gene expression changes that may be targetable cancer "drivers." Aberrant pathways are matched to drug databases, and this data is reported to the clinician for each individual patient. The study was approved by the University of British Columbia Research Ethics Committee (REB# H14-00681), and written informed consent was obtained from each patient prior to genomic profiling. Patient identity was anonymized within the research team, and an identification code was assigned to the case for communicating clinically relevant information to physicians. The patients consented to potential publication of findings. Raw sequence data and downstream analytics were maintained within a secure computing environment.

Whole-Genome and Transcriptome Sequencing

Fresh tumor biopsy and a blood sample were collected for comprehensive DNA and RNA sequencing as previously described (Laskin et al. 2015). Briefly, the mean redundant depth of coverage for the constitutional and tumor samples was ~40× and ~80×, respectively and transcriptomes of ~200,000,000 reads were generated. Somatic point mutations, small insertions or deletions (indels), and copy-number alterations, detected in the tumor DNA but not in the germline, were identified. De novo assembly of genomic and transcriptomic data was performed to detect rearrangements. Publicly available transcriptome sequencing data from the Illumina BodyMap and TCGA were used to explore the expression profile of human genes and transcripts. A within-sample expression rank was also calculated to further infer significance to outlier gene expression levels. For details regarding the genomic and transcriptomic analyses refer to Supplemental File 1. For information about the number of reads and sequencing coverage for genes listed in Tables 1 and 2, refer to Supplemental File 2.

Proteomic Analysis

Tissue Lysis and Enzymatic Digestion

Tissue processing was carried out as described previously (Hughes et al. 2016). FFPE tissue sections (2 × 10-μm scrolls per technical replicate) were provided on glass slides for processing. Tissue was scraped off of each slide and lysed with buffer consisting of 100 mM HEPES pH 8 (CAT#H3375, Sigma-Aldrich), 4% SDS (CAT#L6026, Sigma-Aldrich), 10mM TCEP (CAT#C4706, Sigma-Aldrich), 40mM CAA (CAT#C0267, Sigma-Aldrich), and 1× complete protease inhibitor—EDTA free (CAT#4693159001, Sigma-Aldrich). Mixtures were heated for 90 min at 90°C, and chilled to room temperature for a further 15 min. Prior to digestion, samples were cleaned using a variation on the SP3 protocol (Hughes et al. 2014). Briefly, to each protein mixture to be treated, 200 μg of SP3 beads was added and mixed by pipetting to generate a homogeneous solution. To induce protein binding to the beads, a volume equivalent to that of the sample of acetonitrile was added to achieve a final proportion of 50% by volume. Bead-protein solutions were mixed to ensure a homogeneous distribution of the beads and incubated for a total of 10 min at room temperature. After incubation, tubes were placed on a magnetic rack for 2 min and the supernatant discarded. After incubation, and while on the magnet, the supernatant was removed and discarded. The beads were rinsed twice while on the magnetic rack through addition of 180 μl of freshly prepared 70% absolute ethanol, and the supernatant was discarded each time. Beads were then rinsed one further time while on the magnetic rack with 180 μl of 100% ethanol, and the supernatant discarded. Rinsed beads were reconstituted in aqueous buffer (~50 μl, 0.2 M HEPES, pH 8) containing a 1:50 (μg:μg) enzyme to protein amount of trypsin/rLysC mix (Promega, CAT#V5071), and briefly sonicated in a water bath (30 sec) to disaggregate the beads. Mixtures were incubated for 14 h at 37°C in a PCR thermocycler. After incubation, the tubes were sonicated briefly (10 sec) in a water bath to resuspend the beads. The supernatants were recovered using a magnetic rack and transferred to fresh 1.5 ml polypropylene microtubes.

TMT Labeling

TMT 6-plex labeling kits were obtained from Pierce. Each TMT label (5 mg per vial) was reconstituted in 500 μl of acetonitrile and frozen at −80°C. Prior to labeling, TMT labels were removed from the freezer and allowed to equilibrate at room temperature. Labeling reactions were carried out through addition of TMT label in two volumetrically equal steps to achieve a 2:1 (μg:μg) TMT label to peptide final concentration, 30 min apart. All incubations

were carried out at room temperature. Reactions were quenched by addition of 10 µl of 1 M glycine solution. Labeled peptides were concentrated in a SpeedVac centrifuge to reduce acetonitrile, combined, and run through a SepPak cartridge (Waters, Inc.) for clean-up prior to HPLC fractionation.

HPLC Fractionation

High-pH reversed phase analysis was performed on an Agilent 1100 HPLC system equipped with a diode array detector (254, 260, and 280 nm). Fractionation was performed on a Kinetix EVO C18 column (2.1 × 150-mm, 1.7-µm core shell, 100 Å, Phenomenex). Elution was performed at a flow rate of 0.2 ml per minute using a gradient of mobile phase A (10 mM ammonium bicarbonate, pH 8) and B (acetonitrile), from 3% to 35% over 60 min. Fractions were collected every minute across the elution window for a total of 48 fractions, which were concatenated to a final set of 12 (e.g., 1 + 13 + 25 + 37 = fraction 1). Fractions were dried in a SpeedVac centrifuge and reconstituted in 1% formic acid with 1% DMSO in water prior to MS analysis.

Mass Spectrometry Analysis

Analysis of TMT-labeled peptide fractions was carried out on an Orbitrap Fusion Tribrid MS platform (Thermo Scientific). Samples were introduced using an Easy-nLC 1000 system (Thermo Scientific). Columns used for trapping and separations were packed in-house. Trapping columns were packed in 100 µm internal diameter capillaries to a length of 25 mm with C18 beads (Reprosil-Pur; Dr. Maisch; 3-µm particle size). Trapping was carried out for a total volume of 10 µl at a pressure of 400 bar. After trapping, gradient elution of peptides was performed on a C18 (Reprosil-Pur; Dr. Maisch; 1.9-µm particle size) column packed in-house to a length of 15 cm in 100-µm internal diameter capillaries with a laser-pulled electrospray tip and heated to 45°C using AgileSLEEVE column ovens (Analytical Sales and Service). Elution was performed with a gradient of mobile phase A (water and 0.1% formic acid) and B (acetonitrile and 0.1% formic acid) over 120 min at a flow rate of 300 nl/min.

Data acquisition on the Orbitrap Fusion (control software version 2.1.1565.20) was carried out using a data-dependent method with multinotch synchronous precursor selection MS3 scanning for TMT tags. Survey scans covering the mass range of 350–1500 were acquired at a resolution of 120,000 (at m/z 200), with quadrupole isolation enabled, an S-Lens RF Level of 60%, a maximum fill time of 50 msec, and an automatic gain control (AGC) target value of 5×10^5. For MS2 scan triggering, monoisotopic precursor selection was enabled, charge state filtering was limited to 2–4, an intensity threshold of 5×10^3 was used, and dynamic exclusion of previously selected masses was enabled for 60 sec with a tolerance of 20 ppm. MS2 scans were acquired in the ion trap in Rapid mode after CID fragmentation with a maximum fill time of 150 msec, quadrupole isolation, an isolation window of 1 m/z, collision energy of 30%, activation Q of 0.25, injection for all available parallelizable time turned OFF, and an AGC target value of 4×10^3. Fragment ions were selected for MS3 scans based on a precursor selection range of 400–1200m/z, ion exclusion of 20 m/z low and 5 m/z high, and isobaric tag loss exclusion for TMT. The top 10 precursors were selected for MS3 scans that were acquired in the Orbitrap after HCD fragmentation (NCE 60%) with a maximum fill time of 150 msec, 50,000 resolution, 110–750 m/z scan range, ion injection for all parallelizable time turned OFF, and an AGC target value of 1×10^5. The total allowable cycle time was set to 4 sec. MS1 and MS3 scans were acquired in profile mode, and MS2 in centroid format.

Mass Spectrometry Data Analysis

Data from the Orbitrap Fusion were processed using Proteome Discoverer Software (ver. 2.1.1.21). MS2 spectra were searched using Sequest HT against a combined UniProt Human proteome database appended to a list of common contaminants (24,624 total sequences). Sequest HT parameters were specified as: trypsin enzyme, 2 missed cleavages allowed, minimum peptide length of 6, precursor mass tolerance of 20 ppm, and a fragment mass tolerance of 0.6. Oxidation of methionine and TMT at lysine and peptide amino-termini were set as variable modifications. Carbamidomethylation of cysteine was set as a fixed modification. Peptide spectral match error rates were determined using the target-decoy strategy coupled to Percolator modeling of positive and false distributions (Käll et al. 2007; Spivak et al. 2009). Data were filtered at the peptide spectral match level to control for false discoveries using a q-value cutoff of 0.01 as determined by Percolator. Data sets generated in Proteome Discoverer were exported and analyzed with a combination of scripts built in R designed in-house. Contaminant and decoy proteins were removed from all data sets prior to downstream analysis.

ADDITIONAL INFORMATION

Data Deposition and Access

The whole-genome sequencing and RNA-seq data for these cases are available as .bam files from the European Genome-phenome Archive (EGA; www.ebi.ac.uk/ega/home) as part of the study EGAS00001001159, accession IDs: EGAD00001003660 (Patient 1); EGAD00001003620 (Patient 2). The interpreted sequence variants listed in Tables 1 and 2 have been deposited in the ClinVar public archive (https://www.ncbi.nlm.nih.gov/clinvar/) and can be found under the accession numbers SCV000693729 (NM_006218.3:c.112C>T), SCV000693730 (NM_000038.5:c.847C>T), SCV000693731 (NM_000038.5(APC):c.3927_3931delAAAGA), SCV000693732 (NM_000546.5:c.919+1G>T), SCV000693733 (NM_000038.5:c.1682delA and NM_000038.5:c.3956delC), and SCV000693734 (NM_000546.5:c.743G>A).

Ethics Statement

This work, including data deposition, was approved by the Research Ethics Board at the British Columbia Cancer Agency, protocol H14-00681. Written consent was obtained from the patients after discussion with their oncologists.

Author Contributions

D.R.O. is the primary author of the manuscript. H.W., D.J.R., and H.L. authored the clinical presentations and made substantial edits to the manuscript. M.B. and M.J. performed data collection and analysis and prepared the figures and table. C.S.H. and G.B.M. acquired

and analyzed the proteomics data and authored the methodology for the proteomics. S.J.M.J., J.L. and M.M. contributed to the conception and design of the study; J.L. and M.M. are principal investigators of the POG Clinical Trial. S.Y. and D.F.S. performed pathologic analysis, contributed to the conception and design of the study, and made edits to the manuscript. All authors approved the final manuscript.

REFERENCES

Ahmad R, Alam M, Hasegawa M, Uchida Y, Al-Obaid O, Kharbanda S, Kufe D. 2017. Targeting MUC1-C inhibits the AKT-S6K1-eIF4A pathway regulating TIGAR translation in colorectal cancer. *Mol Cancer* **16:** 33.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al. 2013. Signatures of mutational processes in human cancer. *Nature* **500:** 415–421.

Asonuma K, Date Y, Tsukuda G, Hirabayashi K, Wada Y, Takahashi H, Kunimura T, Hamatani S, Morohoshi T. 2013. Expression of HER2 and MUC1 in advanced colorectal cancer: frequency and clinicopathological characteristics. *Showa Univ J Med Sci* **25:** 93–100.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* **376:** 687–697.

Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD. 2016. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. *Clin Cancer Res* **22:** 3755–3763.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. *Cancer Cell* **12:** 395–402.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, et al. 2011. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discov* **1:** 508–523.

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, et al. 2015. The genomic landscape of response to EGFR blockade in colorectal cancer. *Nature* **526:** 263–267.

Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. 2011. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. *Cancer Cell* **19:** 58–71.

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, et al. 2011. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. *J Clin Oncol* **29:** 166–173.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P. 2010. Effects of *KRAS, BRAF, NRAS,* and *PIK3CA* mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* **11:** 753–762.

Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, et al. 2008. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. *Cancer Res* **68:** 9221–9230.

Freed-Pastor WA, Prives C. 2012. Mutant p53: one name, many proteins. *Genes Dev* **26:** 1268–1286.

Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, et al. 2011. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. *Proc Natl Acad Sci* **108:** 5021–5026.

Hughes CS, Foehr S, Garfield DA, Furlong EE, Steinmetz LM, Krijgsveld J. 2014. Ultrasensitive proteome analysis using paramagnetic bead technology. *Mol Syst Biol* **10:** 757.

Hughes CS, McConechy MK, Cochrane DR, Nazeran T, Karnezis AN, Huntsman DG, Morin GB. 2016. Quantitative profiling of single formalin fixed tumour sections: proteomics for translational research. *Sci Rep* **6:** 34949.

Jensen K, Krusenstjerna-Hafstrøm R, Lohse J, Petersen KH, Derand H. 2017. A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2. *Mod Pathol* **30:** 180–193.

Jeong JH, Kim J, Hong YS, Kim D, Kim JE, Kim SY, Kim KP, Yoon YK, Kim D, Chun SM, et al. 2017. HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF. *Clin Colorectal Cancer* **16:** e147–e152.

Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. 2009. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. *Cancer Cell* **15:** 429–440.

Käll L, Canterbury JD, Weston J, Noble WS, MacCoss MJ. 2007. Semi-supervised learning for peptide identification from shotgun proteomics datasets. *Nat Methods* **4:** 923–925.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, et al. 2014. *PIK3CA*, *BRAF*, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. *Clin Cancer Res* **20:** 744–753.

Kufe DW. 2013. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. *Oncogene* **32:** 1073–1081.

Laskin J, Jones S, Aparicio S, Chia S, Ch'ng C, Deyell R, Eirew P, Fok A, Gelmon K, Ho C, et al. 2015. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. *Cold Spring Harb Mol Case Stud* **1:** a000570.

Lee KH, Kim JS, Lee CS, Kim JY. 2015. KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers. *J Surg Oncol* **111:** 1059–1064.

Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D. 2003. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. *Mol Cancer Res* **1:** 765–775.

Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García-Alfonso P, Donnay O, Carrato A, Jiménez A, Aranda E, et al. 2015. Prognostic value of *BRAF*, *PI3K*, *PTEN*, *EGFR* copy number, amphiregulin and epiregulin status in patients with *KRAS* codon 12 wild-type metastatic colorectal cancer receiving first-line chemotherapy with anti-EGFR therapy. *Mol Diagn Ther* **19:** 397–408.

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, et al. 2013. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. *J Natl Cancer Inst* **105:** 960–967.

Lugli A, Zlobec I, Baker K, Minoo P, Tornillo L, Terracciano L, Jass JR. 2007. Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status. *J Clin Pathol* **60:** 534–539.

Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, et al. 2013. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. *Br J Cancer* **108:** 668–675.

Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, et al. 2010. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. *Hum Pathol* **41:** 1577–1585.

Montemurro F, Scaltriti M. 2014. Biomarkers of drugs targeting HER-family signalling in cancer. *J Pathol* **232:** 219–229.

Ooi A, Takehaa T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y. 2004. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. *Mod Pathol* **17:** 895–904.

Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR. 2013. MET and ERBB2 are coexpressed in ERBB2[+] breast cancer and contribute to innate resistance. *Mol Cancer Res* **11:** 1112–1121.

Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, et al. 2013. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2–positive breast cancer in the North Central Cancer Treatment Group N9831 trial. *J Clin Oncol* **31:** 2115–2122.

Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D. 2014. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. *Oncogene* **33:** 3422–3431.

Rimassa L, Bozzarelli S, Cordio S, Toppo L, Lonardi S, Zaniboni A, Bordonaro R, Liguigli W, Zagonel V, Tronconi MC, et al. 2015. Phase II study of tivantinib (ARQ 197) in combination with cetuximab in EGFR inhibitor-resistant, MET-high, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC). *Ann Oncol* **26**(Supplement 4): v108–iv116.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, et al. 2016. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncol* **17:** 738–746.

Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, et al. 2015. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. *Clin Cancer Res* **21:** 569–576.

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, et al. 2017. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology. *Arch Pathol Lab Med* **141:** 625–657.

Shattuck DL, Miller JK, Carraway KL III, Sweeney C. 2008. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. *Cancer Res* **68:** 1471–1477.

Siena S, Bardelli A, Sartore-Bianchi A, Martino C, Siravegna G, Magri A, Leone F, Zagonel V, Lonardi S, Amatu A, et al. 2016. HER2 amplification as a 'molecular bait' for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: the HERACLES-RESCUE trial. *J Clin Oncol* **34**(4_suppl): pTPS774–TPS774.

Spivak M, Weston J, Bottou L, Käll L, Noble WS. 2009. Improvements to the percolator algorithm for Peptide identification from shotgun proteomics data sets. *J Proteome Res* **8:** 3737–3745.

The Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* **487:** 330–337.

Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, et al. 2012. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. *J Clin Oncol* **30:** 2956–2962.

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, et al. 2015. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. *Mod Pathol* **28:** 1481–1491.

Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X. 2011. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. *BMC Cancer* **11:** 248.

Wurz GT, Kao CJ, Wolf M, DeGregorio MW. 2014. Tecemotide: an antigen-specific cancer immunotherapy. *Hum Vaccin Immunother* **10:** 3383–3393.

Yao YL, Shao J, Zhang C, Wu JH, Zhang QH, Wang JJ, Zhu W. 2013. Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. *PLoS One* **8:** e78086.

Zeng Y, Zhang Q, Zhang Y, Lu M, Liu Y, Zheng T, Feng S, Hao M, Shi H. 2015. MUC1 predicts colorectal cancer metastasis: a systematic review and meta-analysis of case controlled studies. *PLoS One* **10:** e0138049.

Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, et al. 2014. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor–producing bystander cell line in patients with metastatic colorectal cancer. *Ann Surg Oncol* **21:** 3931–3937.